Active	Status	Sponsor type	Region	Phase	Filter
18 Active 1 Inactive 19 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

18 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bhandari, Bal Raj
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Recruiting	3	778	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Crohn's Disease	11/24	12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis	Recruiting	3	1063	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis	07/26	12/27
HORIZON, NCT05583344: Phase 2b Study of GSK4532990 in Adults With NASH	Recruiting	2	246	Europe, Canada, Japan, US, RoW	GSK4532990, Placebo	GlaxoSmithKline	Nonalcoholic Fatty Liver Disease	09/25	12/25
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode	Active, not recruiting	N/A	44467	US		Guardant Health, Inc., Premier Research Group plc	Colorectal Cancer	03/24	12/25
NCT03789162: Blood and Stool Sample Collection in Subjects with a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast	Recruiting	N/A	1500	Canada, US		Exact Sciences Corporation	Colorectal Cancer	12/24	12/24
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk	Recruiting	N/A	2500	US	Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test	Exact Sciences Corporation	Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer	01/25	04/26
Bokhart, Gordon
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis	Recruiting	2	400	US	CIN-102 Dose 1, CIN-102 Dose 2, Placebo	CinDome Pharma, Inc.	Diabetic Gastroparesis	10/24	10/24
Campos, Luciana Teixeira de
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2	Recruiting	3	612	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Recruiting	3	778	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Crohn's Disease	11/24	12/26
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
NCT05298657: The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment	Not yet recruiting	N/A	200	RoW		Fatima College of Health Sciences, ART Fertility Clinics LLC	Poor Response to Ovulation Induction, PCOS, Endometriosis, Infertility, Female	08/24	08/24
Shaikh, Abdul
VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease	Recruiting	4	304	Europe, Canada, US, RoW	Vedolizumab	Alimentiv Inc., Takeda	Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn	01/27	09/28
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Recruiting	3	778	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Crohn's Disease	11/24	12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis	Recruiting	3	1063	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis	07/26	12/27
NCT05480631: COMPARATIVE ANALYSIS OF INNOVATIVE BONE HEALING TECHNIQUES	Recruiting	2/3	60	RoW	autograft, autograft with addition of concenterated growth factor, xenograft with concentrated growth factor	Dow University of Health Sciences	To Assess the Bone Healing in Fracture Mandible Defects	07/22	07/22
Investigator, Hepion
ASCEND, NCT05402371: A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis	Active, not recruiting	2	120	Europe, US, RoW	Rencofilstat, CRV431, Placebo	Hepion Pharmaceuticals, Inc.	Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD	05/25	09/25
Cauvel, Leticia
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis	Recruiting	2	400	US	CIN-102 Dose 1, CIN-102 Dose 2, Placebo	CinDome Pharma, Inc.	Diabetic Gastroparesis	10/24	10/24
Katz, Andrew
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis	Recruiting	2	400	US	CIN-102 Dose 1, CIN-102 Dose 2, Placebo	CinDome Pharma, Inc.	Diabetic Gastroparesis	10/24	10/24